TABLE 3.

Patient cohorts from the published literatures.

Cancer type	Num.	Sequencing platform	TMB threshold	Case
NSCLC	35	F1CDx	≥20 mut/Mb	Goodman et al. (2017)
	57	WES	No definition	Miao et al. (2018)
	75	WES	Median	Hellmann et al. (2018a)
	240	MSK-IMPACT	Median	Rizvi et al. (2018)
Melanoma	37	WES	Top third	Hugo et al. (2016)
	52	F1CDx	≥20 mut/Mb	Goodman et al. (2017)
	64	WES	≥100 mut/Mb	Snyder et al. (2014)
	105	WES	≥100 mut/Mb	Van Allen et al. (2015)
	195 (58) a	WES(MC3)	75th percentiles	Wood et al. (2020)
RCC	56	WES(MC3)	75th percentiles	Wood et al. (2020)
Bladder	27	WES	No definition	Miao et al. (2018)

^aWood2020 study is a pooling meta-analysis on several existing datasets, where 58 patients of the 195 were patients not included in the above studies.